Pharma News

The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.

Merck KGaA reiterated its commitment to investments in the Chinese market with the executive board of Merck KGaA, Darmstadt, Germany, meeting this week met in Shanghai, a month before the groundbreaking of its new pharmaceutical plant in Nantong,...

AstraZeneca reports that MedImmune, its global biologics research and development arm, has entered into a clinical trial collaboration with Advaxis, Inc., a US-based biotechnology company developing cancer immunotherapies. The Phase I/II...

The biopharmaceutical company InterMune, Inc. reports that pirfenidone, an investigational treatment for adult patients with idiopathic pulmonary fibrosis (IFP), has been granted breakthrough therapy designation from the US Food and...

Astellas reports that the US Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive candidiasis.  An invasive fungal infection product that is granted...

Teva Pharmaceutical Industries Ltd. has completed the acquisition of Labrys Biologics Inc,, a privately held development-stage biotechnology company focused on treatments for chronic migraine and episodic migraine. Teva had announced in...

Sandoz, the generics business of Novartis, has formed an agreement with Anacor Pharmaceuticals, Inc., a pharmaceutical company focused on discovering, developing, and commercializing small-molecule therapeutics derived from the company's boron...

AstraZeneca released an update on its new global R&D center and corporate headquarters in Cambridge, UK. The plans for the new facility, which will be located on the Cambridge Biomedical Campus (CBC), include designs for the Global Center,...